Rituximab-induced Cytokine Storm in the Absence of Overt Lymphoproliferative Disease. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Williams, Mark; Khalid, Tasneem; Hughes, Stephen; Bonney, Denise; Wynn, Robert
• Is Part Of: Journal of pediatric hematology/oncology. Volume 38:Issue 1(2016)
• Publication Date: 2016-01
• Subjects: rituximab -- cytokine release syndrome -- cytokine storm; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000000485
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Rituximab is a monoclonal antibody that first demonstrated efficacy in the treatment of lymphoma but has since seen a dramatic growth in its use for other conditions. Cytokine release syndrome (CRS) is a rare but potentially fatal complication of rituximab infusion that has been described in patients with bulky lymphoproliferative disease. Here we report a convincing case of CRS occurring in a patient with no demonstrable lymphoproliferation. This case has implications for our understanding of the pathogenesis of CRS, our attempts to define an at-risk population and the design of future monoclonal antibodies.